Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Avacta Group (AVCT) Share Price

Price 88.50p on 14-05-2026 at 08:00:02
Change -0.50p -0.56%
Buy 90.00p
Sell 87.00p
Last Trade: Sell 3,402.00 at 88.3111p
Day's Volume: 250,902
Last Close: 89.00p
Open: 89.00p
ISIN: GB00BYYW9G87
Day's Range 88.50p - 89.00p
52wk Range: 27.25p - 90.50p
Market Capitalisation: £401.35m
VWAP: 88.60776p
Shares in Issue: 453.51m

Avacta Group (AVCT) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 3,402 88.3111p Ordinary
08:58:22 - 14-May-26
Buy* 10,000 88.70p Ordinary
08:55:54 - 14-May-26
Buy* 1,122 88.80p Ordinary
08:49:32 - 14-May-26
Sell* 4,061 88.2555p Ordinary
08:48:14 - 14-May-26
Sell* 1,022 88.2555p Ordinary
08:47:19 - 14-May-26
Sell* 483 88.2511p Ordinary
08:46:49 - 14-May-26
Buy* 2,245 88.844p Ordinary
08:44:20 - 14-May-26
Buy* 840 88.8956p Ordinary
08:37:47 - 14-May-26
Buy* 1,124 88.8956p Ordinary
08:37:05 - 14-May-26
Buy* 32 88.8956p Ordinary
08:36:07 - 14-May-26
See more Avacta Group trades

Avacta Group (AVCT) Share Price History

Time period:
to
Date Open High Low Close Volume
13th May 2026 (Wed) 84.00 89.50 84.00 89.00 1,373,454
12th May 2026 (Tue) 90.00 90.00 83.50 85.50 3,450,117
11th May 2026 (Mon) 82.50 90.50 88.00 88.00 6,026,785
8th May 2026 (Fri) 82.00 83.00 78.00 82.50 5,285,692
7th May 2026 (Thu) 71.00 82.50 81.00 81.00 6,910,424
6th May 2026 (Wed) 78.00 76.40 71.00 71.00 2,377,307
5th May 2026 (Tue) 74.00 77.50 74.50 77.00 3,007,077
4th May 2026 (Mon) 75.00 75.00 75.00 75.00 0
1st May 2026 (Fri) 73.00 75.00 72.50 75.00 1,637,187
30th Apr 2026 (Thu) 72.00 74.00 74.00 74.00 1,211,042
29th Apr 2026 (Wed) 74.00 74.00 72.00 72.00 1,789,555
28th Apr 2026 (Tue) 75.50 74.00 73.60 73.60 1,158,888
27th Apr 2026 (Mon) 75.50 76.00 74.50 75.50 1,667,214
24th Apr 2026 (Fri) 76.00 76.50 74.30 74.30 1,813,647
23rd Apr 2026 (Thu) 76.50 76.50 74.00 76.50 1,940,829
22nd Apr 2026 (Wed) 80.50 78.50 75.00 75.00 2,251,358
21st Apr 2026 (Tue) 77.00 81.00 77.00 79.60 3,231,700
20th Apr 2026 (Mon) 77.00 78.00 76.50 77.00 1,956,408
17th Apr 2026 (Fri) 74.60 77.00 74.60 77.00 3,224,068
16th Apr 2026 (Thu) 74.50 77.50 74.50 75.00 2,000,664
15th Apr 2026 (Wed) 72.00 76.50 74.00 74.00 3,098,313
14th Apr 2026 (Tue) 69.00 72.50 70.00 72.00 1,917,779
See more Avacta Group price history

Avacta Group (AVCT) Share News

TRADING UPDATES: Vaalco says remainder of 2026 to be "very profitable"

21st Apr 2026 22:53

(Alliance News) - The following is a round-up of updates by London-listed companies, issued last Wednesday and not separately reported by Alliance News: Read More

TRADING UPDATES: Somero Enterprises extends buyback to USD6.0 million

9th Apr 2026 20:07

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

Avacta hails "important milestones" in start of "transformative" year

9th Apr 2026 13:04

(Alliance News) - Avacta Group PLC on Thursday said it "continued to build momentum" in the first quarter, highlighting favourable developments for its oncology products. Read More

IN BRIEF: Avacta raises GBP10 million in equity for clinical tests

27th Mar 2026 09:22

Avacta Group PLC - London-based biopharmaceutical company developing a tumour-activated oncology delivery platform - Raises GBP10 million from a placing of and subscription to 15.9 million new shares at 63 pence each. The new shares represent 3.6% of Avacta's total prior to the issuance. Two non-executive directors, Richard Hughes and David Bryant, contribute a total of GBP550,000 to the raise. The share offer is run by Zeus Capital as broker and bookrunner. Zeus will receive warrants over 4.4 million new shares at the same 63p price, exercisable over five years. The raise is in line with the plan announced after the London market close on Thursday. The fresh cash will be used to progress Avacta's research and development programmes into early in the first quarter of 2027, providing enough cash to get to initial data from a phase 1a trial of AVA6103, its second clinical program. AVA6103, a peptide drug conjugate. Read More

Avacta opens phase 1 trial for conjugate's efficacy regarding tumours

16th Mar 2026 12:00

(Alliance News) - Avacta Group PLC on Monday announced the opening of a phase 1 trial for AVA6103, a peptide-drug conjugate. Read More

See more Avacta Group news
FTSE 100 Latest
Value10,323.02
Change-2.33

Login to your account

Forgot Password?

Not Registered